The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations
Open Access
- 11 December 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1278004
Abstract
BRCA1 is involved in the Fanconi anaemia (FA) pathway, which coordinates repair of DNA interstrand cross-links. FA is a rare genetic disorder characterised by bone marrow failure, cancer predisposition and congenital abnormalities, caused by biallelic mutations affecting proteins in the FA pathway. Germline monoallelic pathogenic BRCA1 mutations are known to be associated with hereditary breast/ovarian cancer, however biallelic mutations of BRCA1 were long predicted to be incompatible with embryonic viability, hence BRCA1 was not considered to be a canonical FA gene. Despite this, several patients with biallelic pathogenic BRCA1 mutations and FA-like phenotypes have been identified – defining a new FA type (FA-S) and designating BRCA1 as an FA gene. This report presents a scoping review of the cases of biallelic BRCA1 mutations identified to date, discusses the functional effects of the mutations identified, and proposes a phenotypic spectrum of BRCA1 mutations based upon available clinical and genetic data. We report that this FA-S cohort phenotype includes short stature, microcephaly, facial dysmorphisms, hypo/hyperpigmented lesions, intellectual disability, chromosomal sensitivity to crosslinking agents and predisposition to breast/ovarian cancer and/or childhood cancers, with some patients exhibiting sensitivity to chemotherapy. Unlike most other types of FA, FA-S patients lack bone marrow failure.Keywords
Funding Information
- NIHR Oxford Biomedical Research Centre
- Academy of Medical Sciences
This publication has 80 references indexed in Scilit:
- BRCA1 and Its Network of Interacting PartnersBiology, 2013
- Analysis of 30 Putative BRCA1 Splicing Mutations in Hereditary Breast and Ovarian Cancer Families Identifies Exonic Splice Site Mutations That Escape In Silico PredictionPLOS ONE, 2012
- Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayGenes & Development, 2012
- Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155Nature Medicine, 2011
- PALB2/FANCN: Recombining Cancer and Fanconi AnemiaCancer Research, 2010
- Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and controlEPMA Journal, 2010
- Characterization ofBRCA1andBRCA2deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE studyHuman Mutation, 2010
- Analysis ofPALB2/FANCN-associated breast cancer familiesProceedings of the National Academy of Sciences, 2007
- Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2Journal of Medical Genetics, 2006
- X-linked inheritance of Fanconi anemia complementation group BNature Genetics, 2004